Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

[1]  K. Pantel,et al.  The 17‐1A antigen is expressed on primary, metastatic and disseminated non‐small cell lung carcinoma cells , 2000, International journal of cancer.

[2]  J. Ferlay,et al.  Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18–29 (1999). , 1999, International journal of cancer.

[3]  D. Bostwick,et al.  Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. , 1999, The Journal of urology.

[4]  J. Ferlay,et al.  Estimates of the worldwide mortality from 25 cancers in 1990 , 1999, International journal of cancer.

[5]  P. Quirke,et al.  Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomas: a potential immunotherapeutic target? , 1999, Journal of clinical pathology.

[6]  H. Rockette,et al.  Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jacques Ferlay,et al.  Estimates of the worldwide incidence of 25 major cancers in 1990 , 1999, International journal of cancer.

[8]  J. Packeisen,et al.  Detection of surface antigen 17-1A in breast and colorectal cancer. , 1999, Hybridoma.

[9]  J. Witte,et al.  Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Fagerberg,et al.  Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A , 1996, Cancer Immunology, Immunotherapy.

[11]  G. Fleuren,et al.  Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model. , 1995, Cancer research.

[12]  J. Fagerberg,et al.  Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. , 1995, Cancer research.

[13]  J. P. Pignon,et al.  Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.

[14]  C. Tangen,et al.  Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report , 1995, Annals of Internal Medicine.

[15]  G. Riethmüller,et al.  Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma , 1994, The Lancet.

[16]  Stephanie Green,et al.  Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.

[17]  J. Fagerberg,et al.  The therapeutic use of monoclonal antibodies in colorectal carcinoma. , 1991, Seminars in oncology.

[18]  S. Jewell,et al.  Tumor-associated antigen expression of primary and metastatic colon carcinomas detected by monoclonal antibody 17-1A. , 1987, American journal of clinical pathology.

[19]  G. Riethmüller,et al.  The epithelial cell surface antigen 17–1A, a target for antibody‐mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies , 1986, International journal of cancer.

[20]  H. Wieand,et al.  Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Michael J. Campbell,et al.  Statistical tables for the design of clinical trials , 1987 .